CureDuchenne Blog


Dyne Therapeutics Series B financing

CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]


Letter to the Community – Myosana Therapeutics

Dear Duchenne Community,  I’m truly thrilled about our investment in a new biotech company called Myosana Therapeutics. Myosana aims to develop next-generation gene therapy for Duchenne muscular dystrophy and neuromuscular diseases. Because of this investment, the team is now positioned to conduct […]

Cure Duchenne News

We remain strong, stable and committed to you

Dear Duchenne Community,   We are proud that, through these difficult times, CureDuchenne is continuing to invest in research, to expand our programs and offer services to the Duchenne Community. All of us are feeling the personal, emotional and financial toll […]

Blog Federal Stimulus Erin

Federal stimulus summary

Author: Erin Frey, Senior Director of Advocacy, CureDuchenne Watching the news over the last few weeks has ranged from confusing to disheartening, overwhelming and sometimes, let’s admit it, a little […]